New progestagens for contraceptive use
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The progestins have different pharmacologic properties depending upon the parent molecule, usually testosterone or progesterone (P), from which they are derived. Very small structural changes in the parent molecule may induce considerable differences in the activity of the derivative. In hormonal contraceptives, progestins represent the major agent designed for suppressing ovulation and are used in combination with estrogen (E) usually ethinyl-estradiol (EE). The development of new generations of progestins with improved selectivity profiles has been a great challenge. Steroidal and nonsteroidal progesterone receptor (PR) agonists have been synthesized as well, although the latter are still in a very early stage of development. Several new progestins, have been synthesized in the last two decades. These include dienogest (DNG), drospirenone (DRSP), Nestorone (NES), nomegestrol acetate (NOMAc) and trimegestone (TMG). These new progestins have been designed to have no androgenic or estrogenic actions and to be closer in activity to the physiological hormone P. DRSP differs from the classic progestins as it is derived from spirolactone. It is essentially an antimineralocorticoid steroid with no androgenic effect but a partial antiandrogenic effect. The antiovulatory potency of the different progestins varies. TMG and NES are the most potent progestins synthesized to date, followed by two of the older progestins, keto-desogestrel (keto-DSG) and levonorgestrel (LNG). The new molecules TMG, DRSP and DNG also have antiandrogenic activity. Striking differences exist regarding the side effects among the progestins and the combination with EE leads to other reactions related to the E itself and whether the associated progestin counterbalances, more or less, the estrogenic action. The 19-norprogesterone molecules and the new molecules DRSP and DNG are not androgenic and, therefore, have no negative effect on the lipid profile. Given their pharmacological properties, it is likely that the new progestins may have neutral effects on metabolic or vascular risks. However, this hypothesis must be confirmed in large clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R., Schweppe, K. W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 745
Oral Contraceptives and the Risk of Breast Cancer
Marchbanks, P. A., McDonald, J. A., Wilson, H. G., Folger, S. G., Mandel, M. G., Daling, J. R., Bernstein, L., Malone, K. E., Ursin, G., Strom, B. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013202 · Cited by 532
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
Kemmeren, J. M., Algra, A., & Grobbee, D. E. (2001) · BMJ · doi:10.1136/bmj.323.7305.131 · Cited by 455
Oral contraceptives and the risk of breast cancer*
(2003) · Obstetrics & Gynecology · doi:10.1097/00006250-200304000-00031 · Cited by 431
Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20710 · Cited by 403
Giangrande, P. H., & McDonnell, D. P. (1999) · PubMed · Cited by 390
Mellick, R. S., Mahler, R. F., & Hughes, B. P. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92145-1 · Cited by 390
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Krattenmacher, R. (2000) · Contraception · doi:10.1016/s0010-7824(00)00133-5 · Cited by 376
Research works printed but not linked: 17
- Bouali, 2001, Gynecol Endocrinol, 15, 48, 10.1080/gye.15.1.48.55 · doi:10.1080/gye.15.1.48.55
- Catherino, 1993, Br J Cancer, 67, 945, 10.1038/bjc.1993.175 · doi:10.1038/bjc.1993.175
- Duc, 1995, Arzneimittelforschung, 45, 70
- Erkkola, 2005, Acta Obstet Gynecol Scand, 84, 207, 10.1111/j.0001-6349.2005.00759.x · doi:10.1111/j.0001-6349.2005.00759.x
- Fotherby, 1990, Contraception, 41, 533, 10.1016/0010-7824(90)90062-Z · doi:10.1016/0010-7824(90)90062-z
- Giangrande, 1999, Recent Prog Horm Res, 54, 291
- Grubb, 2003, Steroids, 68, 921, 10.1016/j.steroids.2003.09.001 · doi:10.1016/j.steroids.2003.09.001
- Maillard-Salin, 2000, Int J Pharm, 199, 29, 10.1016/S0378-5173(00)00357-4 · doi:10.1016/s0378-5173(00)00357-4
- Massai, 2001, Contraception, 64, 369, 10.1016/S0010-7824(01)00259-1 · doi:10.1016/s0010-7824(01)00259-1
- Musgrove, 1991, Mol Cell Biol, 11, 5032
- Nelson, 1996, J Reprod Med, 41, 391
- Noe, 1993, Contraception, 48, 548, 10.1016/0010-7824(93)90117-P · doi:10.1016/0010-7824(93)90117-p
- Odlind, 2002, Acta Obstet Gynecol Scand, 81, 482
- Oelkers, 1995, J Clin Endocrinol Metab, 80, 1816
- Oettel, 2001, Drugs Today, 37, 3
- Paris, 1983, Arzneimittelforschung, 33, 710
- Teichmann, 2003, Climacteric, 6, 17
Cited by
Combined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813.pub2 · Cited by 399
Sex hormones, appetite and eating behaviour in women
Hirschberg, A. L. (2012) · Maturitas · doi:10.1016/j.maturitas.2011.12.016 · Cited by 338
[Ca2+]i signalling in sperm — making the most of what you've got
Publicover, S., Harper, C. V., & Barratt, C. (2007) · Nature Cell Biology · doi:10.1038/ncb0307-235 · Cited by 292
Oral contraceptives containing drospirenone for premenstrual syndrome
Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006586.pub4 · Cited by 270
Sitruk-Ware, R., & Nath, A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.09.004 · Cited by 247
Medical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
Morimont, L., Haguet, H., Dogné, J.-M., Gaspard, U., & Douxfils, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769187 · Cited by 183
The use of newer progestins for contraception
Sitruk-Ware, R., & Nath, A. (2010) · Contraception · doi:10.1016/j.contraception.2010.04.004 · Cited by 174
Self-citationHall, O. J., & Klein, S. L. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.35 · Cited by 173
“For example, depot medroxyprogestone acetate (DMPA) signals through both the PR and glucocorticoid receptor, LNG signals only through the PR, and P4 signals preferentially though the PR but can also signal through the glucocorticoid receptor.(12) As each of these receptors are widely distributed throughout the body, t…”
BackgroundInfluentialSteroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
Lopez, L. M., Grimes, D. A., & Schulz, K. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006133.pub5 · Cited by 166
Metabolic effects of contraceptive steroids
Sitruk-Ware, R., & Nath, A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9182-4 · Cited by 161
“The androgenicity, dose and regimen of progestins determine their effect upon the lipid profile as they oppose some of the estrogenic response [13].”
BackgroundInfluentialSelf-citationÅgren, U. M., Anttila, M., Mäenpää-Liukko, K., Rantala, M.-L., Rautiainen, H., Sommer, W. F., & Mommers, E. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.604450 · Cited by 130
Liu, P. Y., Swerdloff, R. S., Anawalt, B. D., Anderson, R. A., Bremner, W. J., Elliesen, J., Gu, Y.-Q., Kersemaekers, W. M., McLachlan, R. I., Meriggiola, M. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2768 · Cited by 126
“Progestins are known to differ according to rodent antiovulatory potency, ability to support pregnancy, and binding and activation of progesterone (and other steroid) receptors in various cell systems (65).”
BackgroundSelf-citationPiltonen, T., Puurunen, J., Hedberg, P., Ruokonen, A., Mutt, S. J., Herzig, K. H., Nissinen, A., Morin-Papunen, L., & Tapanainen, J. S. (2012) · Human Reproduction · doi:10.1093/humrep/des225 · Cited by 94
Contracepção hormonal e sistema cardiovascular
Brito, M. B., Nobre, F., & Vieira, C. S. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011005000022 · Cited by 78
Dienogest in the treatment of endometriosis
Bizzarri, N., Remorgida, V., Leone Roberti Maggiore, U., Scala, C., Tafi, E., Ghirardi, V., Salvatore, S., Candiani, M., Venturini, P. L., & Ferrero, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.943734 · Cited by 63
Fruzzetti, F., Trémollieres, F., & Bitzer, J. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.662547 · Cited by 56
Evaluation of extended and continuous use oral contraceptives
Johnson, J. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s2143 · Cited by 55
Does the use of hormonal contraceptives affect the mental rotation performance?
Griksiene, R., Monciunskaite, R., Arnatkeviciute, A., & Ruksenas, O. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.03.004 · Cited by 50
Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism
Bastianelli, C., Farris, M., Rosato, E., Brosens, I., & Benagiano, G. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1271708 · Cited by 50
Different cardiovascular effects of progestins according to structure and activity
Nath, A., & Sitruk-Ware, R. (2009) · Climacteric · doi:10.1080/13697130902905757 · Cited by 46
Self-citationHampson, E., Morley, E. E., Evans, K. L., & Fleury, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.888510 · Cited by 17
Metadata
- Authors
- Sitruk-Ware, R.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-16
- Volume
- 12
- Issue
- 2
- Pages
- 169-178
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2100560126
- Cited by
- 362
- References
- 54
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.